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Anticancer drugs kill susceptible cells through induc-
tion of apoptosis. Alterations of apoptotic pathways
in drug-resistant tumor cells leading to apoptosis
de®ciency might represent a potent mechanism con-
ferring drug resistance. We have assessed the effect
of etoposide and cisplatin on the apoptotic pathways
of the drug-sensitive human melanoma cell line
MeWo as well as its etoposide- and cisplatin-resistant
sublines (MeWoEto01, MeWoEto1, and MeWoCis01,
MeWoCis1). Etoposide and cisplatin induced apopto-
sis in drug-sensitive MeWo cells as indicated by
dose-dependent (i) cytochrome c release, (ii) caspase
activation, (iii) DNA fragmentation, and (iv) cleav-
age of poly(ADP-ribose)polymerase. In contrast,
whereas low etoposide-resistant cells (MeWoEto01)
demonstrated reduced but detectable apoptotic
activities, highly etoposide-resistant cells (MeWoEto1)
did not exhibit any of the apoptotic events observed
in etoposide-induced cell death downstream of a
strongly reduced cytochrome c release. Highly cis-
platin-resistant cells (MeWoCis1), however, demon-
strated a reduced caspase 9 activity and cytochrome
c release but the extent of effector caspase activation
as well as DNA fragmentation was comparable to
that of sensitive MeWo cells at equitoxic concentra-
tions. In addition, poly(ADP-ribose)polymerase
cleavage was strongly reduced in highly cisplatin-
resistant sublines. Taken together, sensitive and
drug-resistant MeWo cells utilized different apoptotic
pathways upon drug exposure in a drug-dependent
fashion and apoptosis de®ciency was strongly
associated with the drug-resistant phenotype. Key
words: caspase/cytochrome caspase antibodies/mitochondric.
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C
ommonly used anticancer agents in the treatment of
metastatic melanoma do not result in clinical mean-
ingful responses in most patients (Garbe, 1993)
suggesting a high drug resistance for unknown
reasons. Dacarbazine remains the reference standard
treatment for metastatic melanoma, but only a minority of patients
obtain long-lasting responses (Middleton et al, 2000).
Polychemotherapy regimes have been reported to produce various
response rates. Cisplatin is frequently used in polychemotherapy
regimens in melanoma, but partial response is observed only in
approximately 10%. Treatment with etoposide is more common in
lung cancer, leukemia, and testicular tumors and has been used in
polychemotherapy regimens combined with cisplatin treating
melanoma brain metastases but the response rates remain less than
13% (Fields et al, 1994; Planting et al, 1996).
Biochemical studies have not succeeded in identifying conclu-
sively the basis of resistance in any type of cell selected with
cisplatin and etoposide. In various cell types and using many
approaches several mechanisms, such as DNA repair and DNA
mismatch repair proteins, glutathione metabolism, multidrug-
resistance-related proteins, or the p53 function, have been iden-
ti®ed to be involved in sensitivity towards cisplatin (Niedner et al,
2001; Suzuki et al, 2001). Various mechanisms are discussed to
cause etoposide resistance: topoisomerase II activity (Lage et al,
2000) and the regulation of death-receptor-mediated apoptotic
pathways (Friesen et al, 1999).
Using an in vitro soft agar culture system to predict tumor cell
sensitivity of freshly obtained metastatic melanoma samples, a high
degree of resistance was found against all cytostatic drugs studied,
suggesting the presence of intrinsic cellular mechanisms conferring
drug resistance (Schadendorf et al, 1994). Various mechanisms have
been described as mediating drug resistance in various types of
cancer, but the cellular mechanisms conferring drug resistance in
melanoma are only poorly understood (Schadendorf et al, 1994,
1995a, b, c; Helmbach et al, 2001). In recent years our group has
performed an extensive search for underlying mechanisms. Drug
resistance mediated by membrane transport proteins such as P-
glycoprotein (Schadendorf et al, 1995a), multidrug-resistance-
related protein, or lung resistance protein was analysed
(Schadendorf et al, 1995c) and was found not to be associated
with drug resistance in melanoma. Increased activity of glutathione
S-transferase was demonstrated in gastrointestinal and ovarian
tumors resistant towards alkylating agents (Zhang et al, 1998). Drug
resistance in melanoma cells, however, was not associated with
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elevated GSH activity (Schadendorf et al, 1995b). On the basis of
these analyses based on fresh tumor samples, it can be concluded
that mechanisms commonly known to confer drug resistance in
other tumors seem not to be involved in mediating drug resistance
in melanoma. In order to study drug resistance in greater detail and
to develop concepts for the in vivo situation, a panel of drug-
resistant melanoma cell lines derived from human melanoma cell
line MeWo were established and extensively studied (Kern et al,
1997; Helmbach et al, 2001). MeWo and its drug-resistant sublines
have already been extensively characterized with reference to some
underlying mechanisms possibly conferring drug resistance (Kern et
al, 1997; Lage et al, 1999, 2000; Nessling et al, 1999; RuÈnger et al,
2000; Sinha et al, 2000). Recent studies demonstrated an increased
DNA repair in cisplatin- and fotemustine-resistant melanoma
MeWo cells (Lage et al, 1999). Etoposide-resistant melanoma cells
decreased DNA topoisomerase II activity, corresponding to an
increasing degree of drug resistance (Lage et al, 2000), indicating
that modulation of DNA topoisomerase II activity contributes to
the phenotype of etoposide-resistant cells. As these observations did
not explain the cross-resistance pattern in the panel of drug-
resistant melanoma cells, however, other additional resistance
mechanisms must be operating in these cells.
Recent publications demonstrated that chemotherapeutic agents
exert their cytotoxicity by inducing apoptosis (Friesen et al, 1996;
Fulda et al, 1998b; Houghton, 1999; Sellers and Fisher, 1999;
Kaufmann and Earnshaw, 2000), leading to the attractive concept
that acquired drug resistance may be the result of modulated
apoptotic processes. Resistance to chemotherapy-induced apoptosis
due to modulation of apoptotic pathways has recently been
described in some tumors (Eliopoulos et al, 1995; Segal and
Jacquemin, 1995; Los et al, 1997; Fulda et al, 1998a) and may also
be responsible for drug resistance in melanoma (Jansen et al, 2000b;
Raisova et al, 2000; Franco et al, 2001; Soengas et al, 2001). For
various tumors etoposide and cisplatin were shown to induce
apoptosis (Kuwahara et al, 1975; Seki et al, 1978; von Knethen et al,
1998; Hassan et al, 1999; Siitonen et al, 2000) and resistance toward
these drugs has been associated with alteration of apoptotic
processes (Henkels and Turchi, 1997; 1999; Breton et al, 1998;
Minagawa et al, 1999). Furthermore, recent studies described how
manipulation of apoptotic pathways on different levels could
enhance the apoptotic potential of cancer therapies in tumor cells
(Chmura et al, 1997; Wang et al, 1999; Jansen et al, 2000a).
Apoptosis is a type of cell death involving characteristic
morphologic and biochemical changes, which proceeds in part
via aggregation and multimerization of upstream death effector
molecules that sequentially activate a cascade of caspases (Rathmell
and Thompson, 1999). There are currently two well characterized
caspase-activating cascades that regulate apoptosis: one is initiated
by a cell surface death receptor, e.g., TRAIL, FAS, and the other is
triggered by changes in mitochondrial integrity (Scaf®di et al,
1998). In cells committed to apoptosis the latter is initiated by
mitochondrial cytochrome c release, which binds to apoptotic
protease activating factor 1 and thereby induces conformational
changes of this apoptotic protein followed by recruitment of
caspase 9 to the complex (Zou et al, 1997). The subsequent
autocatalysis of caspase 9 is followed by activation of effector
caspases (e.g., caspase 3, caspase 7) (Li et al, 1997; Zou et al, 1999)
and induction of speci®c endonucleases resulting in DNA
fragmentation (Liu et al, 1997). During apoptosis poly(ADP-
ribose)polymerase (PARP), a nuclear protein involved in DNA
repair (Le Rhun et al, 1998), is known to be one of the earliest
substrates of apoptotic caspase 3 (Lazebnik et al, 1994; Tewari et al,
1995). A recently identi®ed group of proteins regulating apoptosis
is the group of chaperones, which is classi®ed into several major
groups: Hsp90, Hsp70, Hsp60, and the family of small Hsp. It was
recognized that the Hsp may act proapoptotically as well as
antiapoptotically by interacting with speci®c molecules, e.g.,
caspases, in the apoptotic pathway (Bukau and Horwich, 1998;
Garrido et al, 1999; Mosser et al, 2000).
In this report, we have correlated apoptotic features of etopo-
side- and cisplatin-induced cell death in sensitive MeWo cells to
differential expression and activation of apoptotic regulators in
etoposide- and cisplatin-resistant cells. These data help us to
understand the pathways by which etoposide and cisplatin induce
cell death in human melanoma cells and suggest that these pathways
are modulated in resistant melanoma cells. A more thorough
understanding of the apoptosis de®ciency involved in drug
resistance would offer novel possibilities for modulating the clinical
phenotype and consequently overcoming drug resistance in human
melanoma.
MATERIALS AND METHODS
Cell culture The human melanoma cell line MeWo was derived from
a lymph node metastasis of a patient with malignant melanoma at the
Sloan Kettering Cancer Center (NY). Drug-resistant sublines exhibiting
different levels of drug sensitivity were selected in vitro and characterized
as described previously (Kern et al, 1997). Brie¯y, for selection of drug-
resistant cell sublines, MeWo melanoma cells were continuously exposed
to increasing concentrations of chemotherapeutic agents for at least
24 mo. The following drug-resistant MeWo cell sublines show different
levels of resistance and have been maintained for up to 5 y in culture.
The designation of the strains used is as follows: MeWo untreated
(MeWo), MeWo resistant to etoposide 0.1 and 1 mg per ml
(MeWoEto01, MeWoEto1), and MeWo resistant to cisplatin 0.1 and 1 mg
per ml (MeWoCis01, MeWoCis1). Indices indicate drugs and drug doses
used for selection of resistant cell lines. As positive controls in various
experiments the human cervix carcinoma cell line HeLa, the T cell
lymphoma cell line Jurkat, and the Burkitt lymphoma cell line SKW-6.4
were used.
Induction of cell death Twenty-four hours prior to chemotherapeutic
drug treatment, cells were plated into tissue culture dishes. To induce
apoptosis, cells were treated for 72 h at 37°C at equitoxic drug
concentrations (IC75, IC85, IC95) of cisplatin or etoposide. Seventy-two
hours was chosen as an adequate time point after kinetic analysis
revealing representative and reproducible apoptotic features. Cell survival
was determined by counting cells after trypan-blue staining directly after
removal of the drug. Inhibitory concentrations (IC) were calculated with
Table I Sensitivity of MeWo cells and the resistant sublines to cisplatin and etoposide at 72 h exposure timesa
Drug Cell line IC75 (mg per ml) IC85 (mg per ml) IC95 (mg per ml)
Etoposide MeWo 1 (20 6 2.3%) 5 (14 6 2.2%) 10 (7.2 6 2.1%)
MeWoEto01 5 (25.7 6 2.4%) 20 (15.5 6 2.2%) 40 (5.9 6 1.4%)
MeWoEto1 10 (27.2 6 1.4%) 40 (16 6 2.6%) 100 (8.0 6 1.7%)
Cisplatin MeWo 1 (24 6 2.6%) 2 (14.2 6 0.4%) 5 (3.7 6 0.7%)
MeWoCis01 2 (24.4 6 5.5%) 5 (11.2 6 1.3%) 10 (5.0 6 1.7%)
MeWoCis1 5 (24.7 6 1.0%) 10 (15 6 2%) 15 (7.0 6 7.2%)
aSensitivity of MeWo, etoposide-resistant sublines (MeWoEto01 and MeWoEto1), and cisplatin-resistant sublines (MeWoCis1) towards etoposide and cisplatin was assessed
by incubating the cells with drugs over 72 h. Results are the mean of at least triplicate determinations. The IC75, IC85, and IC95 values represent drug concentrations (mg
per ml) that inhibited cell growth by 75%, 85%, and 95%, respectively. The mean of cell survival (%) at the indicated drug concentration as well as the standard deviations
are given in parentheses.
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reference to the untreated control and are shown in Table I. Sensitive
and resistant cells were analyzed at their corresponding IC75, IC85, and
IC95 dose of etoposide and cisplatin, respectively. Live adherent and
nonadherent cells were collected and used for detection of DNA
fragmentation and caspase activity as well as for RNA and protein
isolation.
DNA fragmentation Histone-associated DNA fragments (mono-
nucleosomes and oligonucleosomes) released from nuclear fractions of
drug-treated cells were quanti®ed using a Cell Death Detection ELISA
(Roche, Penzberg, Germany) according to the manufacturer's
instructions. Brie¯y, the sandwich-enzyme immunoassay uses mouse
monoclonal antibodies directed against DNA and histones, respectively.
A ®nal peroxidase substrate reaction is measured as absorbance at
405 nm. Data were normalized against the control and interpreted as
nucleosome enrichment factor (ne-factor). Results are presented as the
mean of at least ®ve experiments.
Western blot analysis Adherent and nonadherent cells were lysed in
buffer (30 mM Tris±HCl, pH 7.5, 150 mM NaCl, 1 mM
phenylmethylsulfonyl ¯uoride and small peptide inhibitors, 1% Triton X-
100, and 10% glycerol). Protein content was determined using a peptide-
binding dye Coomassie Brilliant Blue (Bio-Rad Laboratories, Muenchen,
Germany) followed by photometric measurement at 595 nm. Lysates
were mixed 4:1 with 5 3 sample buffer [50% glycerine, 10% sodium
dodecyl sulfate (SDS), 50 mM Tris (pH 6.8), 25% b-mercaptoethanol,
and 0.25 mg per ml bromophenol blue] and heated at 96°C for 3 min
before loading. Equal amounts of protein were separated by 12% SDS
polyacrylamide gel electrophoresis (SDS-PAGE) at 130 V and blotted at
100 V for 1 h to a Hybond nitrocellulose membrane (Amersham,
Freiburg, Germany) in water-cooled transfer buffer [25 mM Tris±HCl,
0.19 M glycine, 20% methanol, 0.037% (wt/vol) SDS]. Membranes were
blocked with 5% dry-milk in Tween±phosphate-buffered saline (PBS±
0.05% Tween) for at least 1 h and were washed three times in Tween±
Figure 1. DNA fragmentation is induced at
corresponding survival rates in sensitive and
cisplatin-resistant cells but not in etoposide-
resistant cells upon drug treatment. Cell
extracts were prepared following continuous drug
exposure for 72 h. DNA fragmentation is
presented as nucleosomal enrichment factor (ne-
factor) (solid bars) and is correlated to survival rate
(hatched bars). Drug-sensitive MeWo cells were
exposed to etoposide (A-I)and cisplatin (B-I);
low- and high-level etoposide-resistant cells (A-II,
A-III) were treated with etoposide; low- and
high-level cisplatin-resistant cells with cisplatin (B-
II, B-III). The data illustrate the results of an
experimental setup that was repeated at least three
times. Each bar represents the mean of
experiments. The error bars indicate the observed
range, and standard deviations are approximately
50% of these ranges.
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PBS. Membranes were incubated with the relevant primary antibody
overnight at 4°C and subsequently washed three times in Tween±PBS.
The corresponding horseradish peroxidase (HRP) conjugated secondary
antibody was incubated for 1 h at room temperature followed by an
additional washing with Tween±PBS. Proteins were visualized by
enhanced chemoluminescence (Amersham), according to the
manufacturer's recommendations. The membranes were recycled by
incubation in stripping buffer [2% SDS, 62.5 mM Tris (pH 6.7), and
100 mM b-mercaptoethanol] at 56°C for 30 min. To con®rm equivalent
loading and transfer of protein the blot was stained with the protein-
binding dye Ponceau-S (Sigma, Deisenhofen, Germany). An additional
hybridization with a 1:20,000 dilution of the monoclonal mouse anti-b-
actin antibody followed by an incubation with a 1:10,000 diluted
secondary HRP-conjugated antibody was performed. Mouse cytochrome
c antibody and polyclonal caspase 3 antibody were purchased from
Pharmingen (Heidelberg, Germany), and polyclonal caspase 7 antibody
from Oncogen (Boston, MA). Rabbit anti-PARP was purchased from
Roche (Mannheim, Germany) and the cytochrome-c-oxidase antibody
was purchased from MoBiTec (GoÈttingen, Germany).
PARP Western blots have been evaluate by densitometry under
consideration of the reduction of 116 kDa full-length PARP as well as
the increase of the 89 kDa cleavage product.
RNase protection assay Cells (5 3 106) were plated in 182 cm2
tissue culture ¯asks and cultured 24 h before drug treatment as indicated.
Total RNA was isolated using the RNeasy Kit (Quiagen, Hilden,
Germany) according to the manufacturer's recommendations. The
presence of transcripts of caspase 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 was
analyzed using the hApo-1c multiprobe template set (Pharmingen,
Hamburg, Germany). Transcripts of members of the inhibitor of
apoptosis protein (IAP) family (XIAP, survivin, c-IAP-1, c-IAP-2,
NAIP, and TRPM-2) were analyzed using the hAPO-5c multiprobe
template set (Pharmingen). In these template sets L32 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are included as
internal controls. Probe synthesis, hybridization, and RNase treatment
were performed with the RiboQuant Multi-Probe RNase Protection
Assay System according to the manufacturer's instructions (Pharmingen).
Finally, samples were analyzed by electrophoresis on denaturating
polyacrylamide gel (5%) and quanti®ed by autoradiography.
Leu-Glu-His-Asp 7-amino-4-tri¯uoromethyl coumarin (LEHD±
AFC) cleavage assay For the speci®c quantitative in vitro
determination of caspase 9 activity a ¯uorometric immunosorbent
enzyme assay (R&D Systems, Wiesbaden, Germany) was used according
to the manufacturer's recommendations. Brie¯y, 2 3 106 drug-treated or
untreated cells were lysed in buffer. Protein contents were determined
(see above) in order to use equal amounts. The lysates were incubated
with the ¯uorogenic substrate LEHD±AFC (R&D Systems) at 37°C for
at least 1 h. The ¯uorescence, directly proportional to enzymatic activity,
was measured in a ¯uorescent microtiter plate reader every 30 min up to
3 h with a 409 nm excitation ®lter and a 500 nm emission ®lter. Data
were normalized against the untreated control and interpreted as a factor
of fold induction. Results are presented as one typical experiment of at
least three.
Asp-Glu-Val-Asp (DEVD) AFC cleavage assay For the speci®c
quantitative in vitro determination of caspase-3-like activity a
¯uorometric immunosorbent enzyme assay (Roche) was used according
to the manufacturer's recommendations. Brie¯y, active caspase 3 was
bound by a monoclonal mouse anti-caspase-3 antibody to a microtiter
plate. After washing the ¯uorogenic substrate Ac-DEVD-AFC was added
and cleavage rate was measured by ¯uorescent microplate reader after 1 h
with a 409 nm excitation ®lter and a 500 nm emission ®lter. Data were
normalized against the untreated control and interpreted as a factor of
fold induction. They are presented as one typical experiment of at least
three. The speci®city of this assay was also con®rmed using the speci®c
caspase 3 inhibitor DEVD-CHO (Calbiochem, Gieûen, Germany) (data
not shown).
Preparation of cytosolic extracts for cytochrome c release For
subcellular fractionation Apo Alert Cell Fractionation Kit (Clontech,
Heidelberg, Germany) was used according to the manufacturer's
recommendations. Brie¯y, untreated or treated cells (1 3 107) were
washed in PBS and incubated on ice in 300 ml lysis buffer. Cells were
lysed with strokes of a dounce homogenizer (Weathon) using a tight
pestle and centrifuged (900 3 g for 10 min, 4°C) to remove unbroken
cells and nuclei. The mitochondria were pelleted by centrifugation
(15,000 3 g for 25 min, 4°C), resuspended in 80 ml lysis buffer, and
stored at ±20°C until use. The supernatant was ultracentrifuged at
100,000 3 g for 1 h (4°C). The resultant supernatant was designated as
cytoplasmic fraction and stored at ±20°C until use. Protein content was
determined using a peptide-binding dye Coomassie Brilliant Blue (Bio-
Rad Laboratories) followed by photometric measurement at 595 nm.
Lysates were mixed 4:1 with 5 3 sample buffer [50% glycerine, 10%
SDS, 50 mM Tris (pH 6.8), 25% b-mercaptoethanol, and 0.25 mg per
ml bromophenol blue] and heated at 96°C for 3 min before loading on a
12% SDS polyacrylamide gel. Lysates were analyzed by Western blot.
Immunostaining and confocal microscopy Cells were grown in
24-well plates on an object slide for 24 h prior to exposure to etoposide
or cisplatin in a dose corresponding to the respective IC95, as
demonstrated in Table I. After 72 h continuous drug exposure cells
were washed twice in PBS and ®xed for 20 min at room temperature
with 2% paraformaldehyde. Cells were blocked for 10 min with
Figure 2. PARP cleavage upon drug
treatment is detectable in drug-sensitive and
cisplatin-resistant MeWo cells but not in
etoposide-resistant cells. Expression of full-
length PARP and PARP cleavage in drug-
sensitive and drug-resistant MeWo cells detected
by Western blot analysis. Polyclonal rabbit anti-
PARP (1:10000 in Tween±PBS) and HRP-
conjugated antirabbit antibody (1:5000 in Tween±
PBS) were used. Full-length PARP and PARP
cleavage fragments were detected in etoposide-
and cisplatin-treated (A-I, B-I)sensitive MeWo
cells, as well as in etoposide-treated MeWoEto01
and MeWoEto1 cells (A-II, A-III) and cisplatin-
treated MeWoCis01 and MeWoCis1 cells (B-II, B-
III). Untreated (lane 1) and treated (IC75, IC85,
and IC95) (lanes 2±4, respectively) cells were
compared. The positions of full-length PARP
(116 kDa) and its cleavage fragment (89 kDa) are
presented on the right by arrows. Equal amounts
of protein were con®rmed by detection of
b-actin, as denoted on the right. This blot
illustrates one representative Western blot of at
least three. (n.d., not determined.)
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PBS±fetal bovine serum before incubation with the anticytochrome
antibody (1:200) (aAB6H2.B4, Pharmingen) for 1 h at room temperature
revealed by a goat antimouse IgG ¯uorescein isothiocyanate (FITC)
conjugate (1:200) (Southern Biotechnologies). Cells were counterstained
with DAPI and covered with mounting medium. Slides were viewed
with a Zeiss Axioplan confocal microscope. The images were transferred
to Adobe Photoshop software for evaluation. At least three representative
images were taken from each sample.
RESULTS
DNA fragmentation and PARP cleavage upon drug
treatment is de®cient in etoposide-resistant cells DNA
fragmentation and PARP cleavage are considered as ultimate
features of programmed cell death. Therefore, we analysed the
response of drug-sensitive and drug-resistant MeWo cells to
etoposide and cisplatin. The IC75, IC85, and IC95 values,
representing drug concentrations necessary to kill 75%, 85%, or
95%, respectively, of the cells after 72 h of continuous drug
treatment, were determined and are illustrated in Table I. In
parental, drug-sensitive MeWo cells etoposide (Fig 1A-I) and
cisplatin (Fig 1B-I) induced apoptotic cell death as indicated by
decreasing survival rates (hatched bars), which were paralleled by
increasing DNA fragmentation (solid bars). Low-level etoposide-
resistant cells (MeWoEto01, Fig 1A-II) needed increased drug
concentrations to reach comparable IC values; however, DNA
fragmentation was just as high as in sensitive MeWo cells at the
corresponding IC (Figs 1A-I, 1A-II). In contrast, highly
etoposide-resistant cells (MeWoEto1, Fig 1A-III) demonstrated a
dramatically reduced DNA fragmentation at the corresponding IC
compared to sensitive cells. These cells showed no increase in DNA
fragmentation at any drug concentration tested. In contrast,
cisplatin-resistant cells (MeWoCis01 and MeWoCis1, Figs 1B-II,
1B-III) did not demonstrate a de®cient DNA fragmentation
compared to sensitive MeWo cells at the corresponding IC.
In addition, cleavage of PARP was detected in sensitive MeWo
cells in a dose-dependent manner upon exposure to etoposide and
cisplatin, indicating apoptotic cell death (Figs 2A-I, 2B-I, lanes 2±
4). Densitometric analysis revealed an up to 16-fold reduction of
the 116 kDa PARP and an up to 35-fold increase of the 89 kDa
cleavage product in sensitive cells upon etoposide exposure.
Similarly, the 89 kDa cleavage product increased up to 35-fold
upon cisplatin exposure. In MeWoEto01 cells PARP cleavage was
slightly reduced at IC85 and IC95 in response to etoposide
compared to parental MeWo cells (Fig 2A-II), which was
paralleled by the densitometric analysis. In contrast, high level
resistant MeWoEto1 did not exhibit any 89 kDa PARP fragment
(Fig 2A-III) and no change in 116 kDa and 89 kDa fragment
levels were detectable by densitometry. In contrast, highly
cisplatin-resistant cells (MeWoCis1) demonstrated a signi®cant
reduced PARP cleavage in response to cisplatin (Fig 2B-III) (up
to 4.5-fold increase of the 89 kDa cleavage product at IC95 by
densitometry), whereas MeWoCis01 cells still exhibited degradation
of PARP (40-fold by densitometry at IC95) (Fig 2B-II).
Effector caspase activation is de®cient in etoposide-resistant
cells As drug-induced DNA fragmentation and PARP cleavage
at equitoxic concentrations in parental and resistant cells was
altered, this observation prompted us to study the activation of
effector caspases, e.g., caspase 3 and 7, in these cells by cleavage of
¯uorogenic substrates. The synthetic ¯uorogenic peptide Ac-
DEVD-AFC was used to detect caspase-3-like activity (Garcia
Calvo et al, 1999). Following 72 h treatment of sensitive MeWo
cells with etoposide and cisplatin DEVD-AFC cleavage activity
increased from »27-fold (IC75) to »46-fold (IC95) (Fig 3A, left
panel) and »4-fold (IC75) to »16-fold (IC95) (Fig 3B, left panel),
respectively. In comparison to parental MeWo cells, MeWoEto01
exhibited a strongly decreased DEVD±AFC cleavage. Nevertheless,
a clear dose-dependent increase of DEVD±AFC cleavage activity
from »7-fold (IC75) to »18-fold (IC85) and »22-fold (IC95) was still
demonstrable (Fig 3A, middle panel). MeWoEto1 cells, however,
demonstrated a dramatically restricted DEVD±AFC cleavage
activity at IC75. In addition, after exposure to maximum drug
doses (up to IC95) no signi®cant DEVD±AFC cleavage was
inducible in these cells (Fig 3A, right panel). In comparison, in
cisplatin-resistant MeWoCis1 cells DEVD±AFC cleavage activity
increased dose-dependently in response to cisplatin (Fig 3B, right
panel). This cleavage activity was only slightly reduced compared to
cisplatin-treated sensitive MeWo cells at the corresponding IC75,
IC85, or IC95 (Fig 3B, left panel).
Because of the differential cleavage activity of DEVD±AFC
(Fig 3), a substrate thought to be preferred by caspase 3 and 7, we
assessed the activation of these caspases by Western blot analysis
(Fig 4). No differences in the expression of full-length caspase 3
and full-length caspase 7 in sensitive and resistant MeWo cells were
observed (data not shown). Cleavage of caspase 3 to the 17 kDa
fragment as well as cleavage of caspase 7 into the 20 kDa fragment
were detected in sensitive MeWo cells upon etoposide (at IC85 and
IC95) (Figs 4A, 4C-I, lanes 3±4) and cisplatin exposure (IC95)
(Figs 4B, 4D-I, lane 4), indicating caspase 3 and caspase 7
activation in apoptotic cell death upon contact to both drugs.
Figure 3. Effector caspases are not activated in drug-treated etoposide-resistant cells but in sensitive and cisplatin-resistant cells. Effector
caspase activity (caspase-3-like activity) measured as DEVD±AFC cleavage in etoposide- and cisplatin-treated sensitive and resistant MeWo cells by a
¯uorogenic assay. Cell extracts were prepared following 72 h of continuous drug exposure at the respective IC75, IC85, and IC95 as described in
Materials and Methods. (A) Etoposide-treated sensitive cells (MeWo) and etoposide-resistant cells (MeWoEto01 and MeWoEto1); (B)cisplatin-treated
sensitive cells (MeWo) and cisplatin-resistant MeWo cells (MeWoCis1). The data were normalized against the respective untreated control (®) and are
shown as x-fold induction. Each bar represents the mean of ®ve experiments. The error bars indicate the observed range, and standard deviations are
approximately 50% of these ranges.
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Consistent with the DEVD±AFC cleavage activity (Fig 3A),
caspase 3 activation, detected by Western blot, in MeWoEto01
cells was signi®cantly reduced at IC85 and IC95 in response to
etoposide (Fig 4A-II, lanes 3, 4). Highly resistant MeWoEto1 cells
did not exhibit cleavage fragments (Figs 4A, 4C-III). In compari-
son, low cisplatin-resistant cells, MeWoCis01, demonstrated a
signi®cantly reduced caspase 3 activation in response to cisplatin
(Fig 4B-II, lane 4). In MeWoCis1 cells proteolytic products of
caspase 3 and 7 could be detected weakly upon cisplatin exposure at
IC95 (Figs 4B, 4D-III, lane 4) in comparison to sensitive cells.
Expression of caspases and inhibitory molecules is not
different in sensitive and resistant cells Activation of caspases
during apoptosis proceeds by stepwise processing of caspases by
other proteases (Martin and Green, 1995); however, the detailed
sequence in this process remains obscure. Our initial results
demonstrated de®ciencies in caspase activation, where various
caspases themselves as well as caspase inhibitors might be
responsible. Expression of caspases was determined on the
mRNA level. Using an RNase Protection Assay, transcripts of all
caspases investigated, except caspase 10, were present (Fig 5A). On
the mRNA level none of these caspases was differentially expressed,
either in drug-resistant (lanes 6±9) or in untreated or drug-treated
sensitive MeWo cells (lanes 1±5). Additional Western blot analysis
of total cellular protein lysates con®rmed that expression levels of
caspase 3, 7, and 9 were not signi®cantly different in sensitive and
resistant cell lines (data not shown). Expression of IAP family
members known to inhibit caspases was determined on the mRNA
level using an RNase Protection Assay (Fig 5B). All cells studied
expressed a comparable pattern of mRNA species encoding XIAP,
survivin, c-IAP-1, and TRPM-2. NAIP and c-IAP-2 speci®c
mRNAs were not detectable (Fig 5B). Additional Western blot
analysis con®rmed that protein levels of cIAP-1, cIAP-2, X-IAP,
and survivin did not differ between drug-sensitive and drug-
resistant cells (data not shown).
Cytochrome c release is strongly reduced in etoposide-
resistant cells Release of cytochrome c from mitochondria into
the cytoplasm has been implicated as an important step in apoptosis
mediated by cytostatic drugs (Liu et al, 1996; Bossy-Wetzel et al,
1998). The extent of cytochrome c translocation from
mitochondria into the cytoplasm in drug-sensitive and drug-
resistant cells after drug exposure was assessed by Western blotting
and immunocytologic staining. Release of cytochrome c in drug-
exposed sensitive MeWo cells (Figs 6A-II, A-IV) was
demonstrated by a diffuse homogeneous staining pattern in
contrast to the untreated control (Fig 6A-I), with a granulated
staining pattern representing a mitochondrial localization of
cytochrome c. This translocation of cytochrome c into the
cytosol was also induced in cisplatin-resistant cells exposed to
cisplatin (Fig 6A-III). Upon etoposide treatment, however,
MeWoEto1 cells exhibited the characteristic granulated FITC
staining beside a slight diffuse FITC staining (Fig 6A-V),
suggesting strongly reduced cytochrome c translocation.
Figure 4. Different activation of caspase 3
and caspase 7 in sensitive and resistant
MeWo cells. Western blot analysis was
performed in drug-sensitive and drug-resistant
MeWo cells using the polyclonal rabbit anticaspase
3 (A, B) (1:2000 in Tween±PBS) and HRP-
conjugated antirabbit antibody (1:5000 in Tween±
PBS) as well as the polyclonal mouse anticaspase 7
(C, D) (1:1000 in Tween±PBS) and HRP-
conjugated antimouse antibody (1:5000 in
Tween±PBS). Expression was detected in
etoposide- and cisplatin-treated sensitive MeWo
cells (A±D/-I), as well as in etoposide-treated
MeWoEto01 and MeWoEto1 cells (A; C-II, C-III)
and cisplatin-treated MeWoCis01 and MeWoCis1
cells (B; D-II, D-III). Untreated (lane 1) and
treated (IC75, IC85, and IC95) (lanes 2±4,
respectively) cells were compared. The positions
of full-length caspase and its cleavage fragment are
denoted on the right. Equal amounts of protein
were con®rmed by detection of b-actin as
denoted by an arrow on the right. This blot
demonstrates one representative Western blot of at
least three. (n.d., not determined.)
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Western blot results presented in Fig 6(B, C) con®rmed minimal
levels of cytochrome c (15 kDa) only in the cytoplasm of extracts
prepared from untreated cells (Figs 6B, C, lane 5). After 72 h
etoposide treatment of sensitive MeWo cells a clear dose-depend-
ent increase of cytoplasmic cytochrome c was detectable (Fig 6B-I,
lanes 6±8). Similar results were obtained after cisplatin exposure of
sensitive MeWo cells (Fig 6C-I, lanes 6±8). In contrast, in
MeWoEto1 cells a strongly reduced release of cytochrome c into
the cytoplasm (Fig 6B-III, lanes 5±8) was observed. Instead, there
was a signi®cant upregulation of mitochondrial cytochrome c in
drug-exposed MeWoEto1 cells (Fig 6B-III, lane 4). We also
performed similar experiments exposing etoposide-resistant cells
to teniposide, another topoisomerase II inhibitor, with identical
results (data not shown). MeWoEto01 cells demonstrated a detect-
able but reduced cytochrome c release (Fig 6B-II). MeWoCis01
cells exhibited a signi®cant cytochrome c release comparable to
sensitive cells (Fig 6C-II). In comparison, highly cisplatin-resistant
cells (MeWoCis1) showed a reduced cytochrome c release into the
cytoplasm at high drug concentrations (IC85, IC95) (Fig 6C-III,
lanes 7, 8) by Western blot analysis.
LEHD±AFC cleavage activity As sensitive and resistant
MeWo cells showed different levels of cytochrome c release,
effector caspase activation, PARP cleavage, and DNA
fragmentation at comparable survival rates, we consequently
analyzed caspase 9 activity by LEHD±AFC cleavage. Caspase 9 is
an initiator caspase promoting apoptotic cell death initiated by
cytochrome c and apoptotic protease activating factor 1. Various
studies have shown that caspase 9 is activated in response to
cytochrome c due to clustering of caspase 9 by apoptotic protease
activating factor 1 (Li et al, 1997; Pan et al, 1998). A preferred
substrate of caspase 9 in vitro is LEHD, which was used to assess
caspase 9 activity in drug-sensitive and resistant MeWo cell lines.
Peptide cleavage was measured in extracts prepared from cells after
72 h of drug treatment and was normalized against the untreated
control. After etoposide exposure of sensitive MeWo cells LEHD±
AFC cleavage activity increased from »4-fold (IC75) to »17-fold
(IC95) dose-dependently (Fig 7A, left panel). In comparison,
etoposide exposure of MeWoEto01 cells resulted in reduced
LEHD±AFC cleavage activity. Nevertheless, this activity still
increased dose-dependently from »2-fold (IC75) up to »8-fold
(IC95) (Fig 7A, middle panel). LEHD-speci®c peptide cleavage
activity could not be detected in extracts prepared from MeWoEto1
cells exposed to etoposide at any concentrations tested (Fig 7A,
right panel). In sensitive MeWo cells cisplatin induced a dose-
dependent LEHD±AFC cleavage activity starting at an »2-fold
induction at IC75 up to an »12-fold induction at IC95 (Fig 7B, left
panel). In MeWoCis1 cells exposed to cisplatin low caspase 9 activity
was measured, which was maximally »2.5-fold induced and did not
increase dose-dependently (Fig 7B, right panel), whereas low-
resistant MeWoCis01 cells demonstrated an »7-fold increase of
LEHD±AFC cleavage at IC85 (Fig 7B, middle panel).
DISCUSSION
Many cytostatic drugs are well known to act through apoptotic
mechanisms. In order to investigate mechanisms conferring drug
resistance towards etoposide and cisplatin, human melanoma
MeWo cells and their resistant variants were analyzed. Apoptotic
cell death in drug-sensitive MeWo cells upon exposure to cisplatin
and etoposide was associated with a dose-dependent DNA
fragmentation and PARP cleavage. Furthermore, cell death was
accompanied by mitochondrial release of cytochrome c into the
cytoplasm, the induction of LEHD±AFC cleavage activity
suggesting the activation of the initiator caspase 9, DEVD±AFC
cleavage activity, and proteolytic degradation of the effector
Figure 5. mRNA of several caspases and members of the IAP family is equally expressed in sensitive and resistant MeWo cells. For
detection of mRNA expression of several (A) caspases and (B) members of the IAP family RNase protection assay was performed. (A) Cells were
treated with cisplatin or etoposide for 20 h. RNA was analyzed from untreated sensitive MeWo cells (lane 1), sensitive cells treated with cisplatin
0.1 mg per ml and 1 mg per ml (lanes 2, 3), sensitive cells treated with etoposide 0.1 mg per ml and 1 mg per ml (lanes 4, 5), MeWoCis01 (lane 6) and
MeWoCis1 (lane 7), and MeWoEto01 (lane 8) and MeWoEto1 (lane 9). Weak signals detected in RNA from MeWo (lane 1) are due to reduced RNA
loading. (B) Cells were treated with cisplatin or etoposide for 20 h. RNA was analyzed from untreated sensitive MeWo cells (lane 1), sensitive MeWo
cells treated with cisplatin 1 mg per ml (lane 2) and etoposide 1 mg per ml (lane 3), MeWoCis1 (lane 4), and MeWoEto1 (lane 5). The undigested probe
(I) was used to establish a standard curve for identifying speci®c RNase-protected bands in the samples. The respective transcripts are denoted on the
left. Equal loading was checked by analyzing the housekeeping genes L32 and GAPDH. RNA loading from cisplatin- and etoposide-resistant cells was
reduced in lanes 4 and 5. Results were con®rmed by one additional RNase protection assay.
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caspases, caspase 3 and caspase 7, determined by Western blot
analysis. Cytochrome c release was strongly reduced in etoposide-
resistant cells. Therefore, this work provides additional evidence
that cisplatin and etoposide resistance is associated with an altered
apoptotic pathway speci®c for the drug employed. These data
further demonstrate that etoposide- and cisplatin-induced apoptosis
in drug-sensitive MeWo cells is mediated by mitochondrial
pathways as has been described for various cytostatic drugs in
other tumor entities previously (Hirsch et al, 1997; Zhao et al, 1998;
Henkels and Turchi, 1999). Taken together the results implicate a
marked apoptosis de®ciency in highly etoposide-resistant cells,
although caspase-independent apoptosis as well as programmed cell
death without DNA fragmentation have been described.
This concept of apoptosis de®ciency is supported by the
observed close association between the gradual loss of apoptotic
features and the increasing level of etoposide resistance at
equitoxic drug concentrations used for exposure. An altered
drug±target interaction cannot be completely ruled out, how-
ever, as in highly etoposide resistant cells (MeWoEto1) a
decrease of topoisomerase activity was observed previously
(Lage et al, 2000), which itself might be in part responsible
for drug resistance. Although etoposide-resistant cells exhibit a
marked cross-resistance towards cisplatin (Kern et al, 1997),
cisplatin exposure of etoposide-resistant cells can reactivate
certain apoptotic characteristics, such as DNA fragmentation
and caspase activation (data not shown).
Figure 6. Cytochrome c release in etoposide-resistant MeWo cells is strongly reduced. Release of cytochrome c was investigated by
immunocytologic staining (A) as well as Western blot analysis (B, C). (A)Untreated nonapoptotic cells are characteristically featured by punctuated
FITC/cytochrome c (green) staining and the intact nucleus (DAPI/blue) (A-I)as seen in the untreated MeWo control. Sensitive and resistant cells were
treated with cisplatin and etoposide, respectively, for 72 h in a concentration that represents the IC95 (Table I). Cisplatin-treated sensitive MeWo cells
(A-II) as well as MeWoCis1 (A-III) demonstrated nucleus fragmentation and a diffuse homogeneous FITC staining representing release of cytochrome c
into the cytosol. This appearance was detectable also in sensitive cells treated with etoposide (A-IV). The staining of drug-exposed highly etoposide-
resistant cells is shown in (A-V)where the granulated cytochrome c-FITC staining and a slight diffuse homogeneous FITC background as well as the
unfragmented nucleus are seen. (B)Treated and untreated cells were collected and subcellular fractions were separated as described in Materials and
Methods. Mitochondrial (lanes 1±4) and cytoplasmic fractions (lanes 5±8) were separated by SDS-PAGE. Western blots were probed with a 1:1000
dilution of a mouse anticytochrome c monoclonal antibody. Sensitive MeWo cells and etoposide-resistant cells, MeWoEto01 and MeWoEto1 (B-I, B-II,
B-III) cells untreated (lanes 1, 5) and treated with etoposide at IC85, IC95, and IC95 (B-I, lanes 2±4, 6±8), were analyzed. The same experiment was
performed with sensitive MeWo cells and cisplatin-resistant cells, MeWoCis01 and MeWoCis1, exposed to cisplatin (C).The position of cytochrome c
(15 kDa) is marked on the right. Equal amounts of protein were con®rmed by detection of b-actin, as denoted by an arrow. The purity of the
subcellular fractions was controlled by additional Western blot analysis with a monoclonal antibody detecting cytochrome-c-oxidase, which is strictly
localized in the mitochondrial membrane (data not shown).
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Taken together, chemotherapeutic drugs, such as etoposide and
cisplatin, induced apoptotic cell death in MeWo cells via involve-
ment of mitochondria. Etoposide- and cisplatin-resistant sublines
derived from MeWo followed different pathways leading to cell
death compared to the sensitive parental cell line. Cell death in
etoposide-resistant MeWo cells was characterized by an absence of
typical hallmarks of apoptosis, implicating an apoptosis de®ciency as
the possible origin of the drug resistance observed. Cisplatin-
resistant cells showed another dramatic modulation of their
apoptotic pathway compared to the sensitive parental as well as
to the etoposide-resistant cell line. Apoptosis in these cells was less
dependent on cytochrome c release and caspase 9 activation and
associated with reduced PARP cleavage. This constellation suggests
a modulation of the apoptotic pathway on the mitochondrial level,
where cytochrome c release and caspase 9 activation is reduced.
High expression of Hsp, namely Hsp70 and Hsp27, in breast,
endometrial, or gastric cancer has been associated with metastasis,
poor prognosis, and resistance to chemotherapy (Maehara et al,
2000; Munster et al, 2001; Wataba et al, 2001). In apoptosis induced
by the anticancer agent etoposide caspase 9, but not cytochrome c
release, is inhibited by Hsp27. Thus, Hsp27 may exert its effect on
the apoptosome (Garrido et al, 1999). This might be a relevant
mechanism in etoposide-resistant cells as we detected here a
remanent cytochrome c release but no activation of caspase 9; this
should be proved in future experiments.
In a recent report (Henkels and Turchi, 1999) cisplatin-induced
apoptosis in cisplatin-sensitive and cisplatin-resistant human ovarian
cancer cell lines was shown to proceed via caspase-3-independent
and caspase-3-dependent pathways, respectively. In that report an
alteration of the apoptotic pathway present in sensitive cells was
associated with the cisplatin-resistant phenotype. Other studies
reported defects in the ability to activate apoptotic processes in a
cisplatin-resistant leukemia cell line, which correlated to a lack of
endonuclease activity and DNA fragmentation (Segal and
Jacquemin, 1995). In cisplatin-resistant human squamous carcino-
ma cells apoptosis de®ciency was associated with Bcl-xL dependent
abrogation of cytochrome c release (Kojima et al, 1998). These
differences emphasize that apoptotic pathways might be dependent
not only on the apoptotic stimulus but also on the cell system.
The differences observed in cisplatin- and etoposide-resistant cells
highlights an important aspect with respect to the transduction of the
cellular signals sensing DNA damage induced by different anticancer
drugs. In any case, it will be of interest to determine the effect of
other apoptotic stimuli on the apoptotic pathway in resistant MeWo
cells. These studies will show whether speci®c apoptotic defects
associated with speci®c drug resistance also confer resistance to other
drugs and if these defects can be bypassed or corrected.
Furthermore, alternative mechanisms leading to drug resistance
such as alterations in DNA mismatch repair (Lage et al, 1999;
RuÈnger et al, 2000) and DNA topoisomerase II activity (Lage et al,
2000) were associated with the acquired etoposide-resistant
phenotype exhibited by MeWoEto1 cells. These data demonstrated
a constitutive decreasing activity of topoisomerase IIb with
increasing etoposide resistance of MeWo cells. Furthermore, Lage
et al (1999) showed a de®ciency in DNA mismatch repair (MMR)
by decreased nuclear MMR protein expression levels (MSH-1,
MSH-6) in fotemustine- and cisplatin-resistant MeWo cells.
RuÈnger et al (2000) demonstrated an increased DNA repair in
the cisplatin-resistant MeWoCis cells and fotemustine-resistant cells
as well. DNA repair might therefore be an essential part in
conferring resistance towards alkylating drugs.
The drug-resistant MeWo cell line represents a unique system to
study underlying drug resistance mechanisms. Work on cell lines
has the advantage of reproducibility; however, whether data
obtained are representative needs to be proven. Nevertheless, the
results obtained might lead to new concepts and might stimulate
further research on fresh tumor samples and other melanoma cell
lines. Differences in drug-induced apoptosis dependent on various
cytostatic drugs have not been analyzed before. Our data provide
further support for the involvement of apoptosis de®ciency in drug
resistance of melanoma and may help towards an understanding of
etoposide- and cisplatin-induced apoptosis and mechanisms con-
ferring chemoresistance towards etoposide and cisplatin in human
melanoma. Moreover, the results support the concept that
modulation of apoptotic pathways in human MeWo cells is drug
dependent and highly associated with the drug-resistant phenotype.
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